Noninvasive Nervous System Gene Delivery Via Engineered Viral Vector
New virus-based vectors that can deliver “genetic cargo” to cells beyond the blood-brain barrier and in neurons throughout the body have been created by researchers at California Institute of Technology. The development may potentially make way for new treatments for diseases like Parkinson’s.
Viruses have evolved to be highly effective vehicles for delivering genes into cells. Seeking to take advantage of these traits, scientists can reprogram viruses to function as vectors, capable of carrying their genetic cargo of choice into the nuclei of cells in the body.
Such vectors have become critical tools for delivering genes to treat disease or to label neurons and their connective fibers with fluorescent colors to map out their locations.
Breaking Through The Blood-brain Barrier
Because viral vectors have been stripped of their own genes and, thereby, of their ability to replicate, they are no longer infectious. Therefore, achieving widespread gene delivery with the vectors is challenging.
This is especially true for gene delivery to hard to reach organs like the brain, where viral vectors have to make their way past the so-called blood-brain barrier, or to the peripheral nervous system, where neurons are dispersed across the body.
Now, to enable widespread gene delivery throughout the central and peripheral nervous systems, researchers have developed two new variants of a vector based on an adeno-associated virus (AAV).
One can efficiently ferry genetic cargo past the blood-brain barrier. Another is efficiently picked up by peripheral neurons residing outside the brain and spinal cord, such as those that sense pain and regulate heart rate, respiration, and digestion.
Both vectors are able to reach their targets following a simple injection into the bloodstream. The vectors are customizable and could potentially be used as part of a gene therapy to treat neurodegenerative disorders that affect the entire central nervous system, such as Huntington’s disease, or to help map or modulate neuronal circuits and understand how they change during disease.
“We have now developed a new collection of viruses and tools to study the central and peripheral nervous systems. We are now able to get highly efficient brain-wide delivery with just a low-dose systemic injection, access neurons in difficult-to-reach regions, and precisely label cells with multiple fluorescent colors to study their shapes and connections,”
Gradinaru and her team modified the external surface of an AAV developed in 2016, engineering the virus’s shell, or capsid, to allow it to more efficiently deliver genes to cells in the brain and spinal cord following intravenous injection. They named the new virus AAV-PHP.eB.
The engineered viral vector AAV-PHP.eB carrying reporter genes controlled by different gene regulatory elements enables expression of a gene of interest in specific cell populations across the adult mouse brain. (A) green fluorescent protein expression from a Purkinje cell-specific promoter; (B) a red fluorescent protein driven by a forebrain inhibitory neuron-restricted promoter. Credit: Chan et al., Gradinaru Lab; Nature Neuroscience
The team also developed an additional capsid variant they call AAV-PHP.S, which is able to transduce peripheral neurons. Ben Deverman, senior research scientist and director of the Beckman Institute’s CLOVER (CLARITY, Optogenetics, and Vector Engineering Research) Center, says:
“Neurons outside of the central nervous system have many functions, from relaying sensory information to controlling organ function, but some of these peripheral neural circuits are not yet well understood. The AAV-PHP.S vector that we developed could help researchers study the activity and function of specific types of neurons within peripheral circuits using genetically-encoded sensors and tools to modulate neuronal firing with light or designer drugs, respectively.”
The new AAV vectors can also deliver genes that code for colorful fluorescent proteins; such proteins are useful in identifying and labeling cells. In this process, multiple AAVs—each carrying a distinct color—are mixed together and injected into the bloodstream.
When they reach their target neurons, each neuron receives a unique combination of colors, thereby giving it a visually distinct hue that makes it easier for the researchers to distinguish its fine details from those of its neighbors.
Furthermore, the team devised a technique to control the number of neurons labeled.
Labeling too many neurons makes it impossible to distinguish individual ones. That allows researchers to visualize individual neuron shapes and trace their connecting fibers through intact tissues using another technology the Gradinaru laboratory has helped develop, known as tissue clearing.
“Usually, when researchers want a mouse or other animal model to express fluorescent proteins in certain cells, they need to develop genetically modified animals that can take months to years to make and characterize,” says first author Ken Chan. “Now with a single injection, we can label specific cells with a variety of colors within weeks after the injection.”
“For our new systemic viral vectors—AAV PHP.S and AAV PHP.eB—there are many potential uses, from mapping circuits in the periphery and fast screening of gene regulatory elements to genome editing with powerful tools such as CRISPR-Cas9. But perhaps the most exciting implication is that our tools, when paired with appropriate activity modulator genes, could enable non-invasive deep brain modulation for the treatment of neurological diseases such as Parkinson’s disease.”
The work was funded by the National Institutes of Health, the Presidential Early Career Award for Scientists and Engineers, the Heritage Medical Research Institute, the Beckman Institute and Rosen Center at Caltech, the Gordon and Betty Moore Foundation, the Shurl & Kay Curci Foundation, the Hereditary Disease Foundation, the Friedreich’s Ataxia Research Alliance (FARA) and FARA Australasia, and the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office.